Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal

Circulation Research
Alberto ZanchettiGianfranco Parati

Abstract

Sixty-eight blood pressure (BP)-lowering randomized controlled trials (defined as randomized controlled trials comparing active treatment with placebo, or less active treatment, achieving a BP difference, performed between 1966 and end 2013 in cohorts with ≥ 40% hypertensive patients, and exclusive of trials in acute myocardial infarction, heart failure, acute stroke, and dialysis) were identified and meta-analyzed grouping the randomized controlled trials on the basis of clinically relevant questions: (1) does BP lowering reduce all types of cardiovascular outcome? (2) Is prevention of all outcomes proportional to the extent of systolic, diastolic, and pulse BP? (3) Have all classes of BP-lowering drugs been shown capable of reducing all types of cardiovascular outcome? (4) Is BP lowering beneficial when intervention is initiated at any grade (or stage) of hypertension? (5) Do BP-lowering randomized controlled trials provide evidence about systolic BP and diastolic BP targets of treatment? (6) Should BP-lowering treatment be preferentially addressed to patients in higher risk categories promising larger absolute treatment benefits? The results of these meta-analyses provide further support to current hypertension treatment gui...Continue Reading

References

Nov 1, 1986·British Medical Journal·J Coope, T S Warrender
Mar 7, 1970·Lancet·A B Carter
Jul 22, 1974·JAMA : the Journal of the American Medical Association
Mar 1, 1966·Journal of Chronic Diseases·F W Wolff, R D Lindeman
Oct 31, 1981·British Medical Journal·M E SpracklingG Watt
Nov 1, 1980·The American Journal of Medicine·A Helgeland
Jan 20, 2000·The New England Journal of Medicine·UNKNOWN Heart Outcomes Prevention Evaluation Study InvestigatorsG Dagenais
Sep 22, 2001·The New England Journal of Medicine·E J LewisUNKNOWN Collaborative Study Group
Sep 22, 2001·The New England Journal of Medicine·B M BrennerUNKNOWN RENAAL Study Investigators
Sep 22, 2001·The New England Journal of Medicine·H H ParvingUNKNOWN Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group
Nov 21, 2002·JAMA : the Journal of the American Medical Association·Jackson T WrightUNKNOWN African American Study of Kidney Disease and Hypertension Study Group
Dec 4, 2002·American Journal of Hypertension·Roberto FogariPierangelo Lazzari
May 30, 1959·British Medical Journal·A W LEISHMAN
Nov 15, 2003·Lancet·Fiona Turnbull, UNKNOWN Blood Pressure Lowering Treatment Trialists' Collaboration
Dec 5, 2003·Journal of Hypertension·Christopher J BulpittUNKNOWN Hypertension in the Very Elderly Trial Working Group
Dec 6, 2003·Hypertension·Aram V ChobanianUNKNOWN National High Blood Pressure Education Program Coordinating Committee
Sep 8, 2004·Lancet·Philip A Poole-WilsonUNKNOWN Coronary disease Trial Investigating Outcome with Nifedipine gastrointestinal therapeutic system investigators
Nov 2, 2004·The New England Journal of Medicine·Piero RuggenentiUNKNOWN Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators
Nov 9, 2004·The New England Journal of Medicine·Eugene BraunwaldUNKNOWN PEACE Trial Investigators
Nov 13, 2004·JAMA : the Journal of the American Medical Association·Steven E NissenUNKNOWN CAMELOT Investigators
May 17, 2005·Journal of Hypertension·Alberto Zanchetti

❮ Previous
Next ❯

Citations

Jan 20, 2016·Expert Review of Cardiovascular Therapy·Daniel T LacklandAndrea D Boan
Jul 19, 2016·Nature Reviews. Nephrology·Giuseppe Mancia
Sep 23, 2016·The New England Journal of Medicine·Eva M LonnSalim Yusuf
Oct 25, 2016·Current Atherosclerosis Reports·Guido GrassiRaffaella Dell'Oro
Jun 3, 2017·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Carlos M Ferrario, Adam E Mullick
Dec 3, 2016·Current Opinion in Neurology·Alexandra YannoutsosJacques Blacher
Oct 17, 2017·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Youbao LiXianhui Qin
Apr 19, 2018·The Cochrane Database of Systematic Reviews·James M WrightRupam Gill
Sep 22, 2017·Therapeutic Advances in Musculoskeletal Disease·Arduino A MangoniRichard J Woodman
Aug 17, 2017·The Cochrane Database of Systematic Reviews·Vijaya M MusiniJames M Wright
Jul 15, 2015·Hypertension·Pietro A Modesti
Mar 15, 2015·Circulation Research·Giuseppe Mancia
Jun 6, 2019·The Cochrane Database of Systematic Reviews·Vijaya M MusiniJames M Wright
Mar 19, 2019·Journal of Hypertension·Patricio López-JaramilloUNKNOWN Latin American Society of Hypertension Consensus Expert Group
Feb 23, 2020·Journal of Alzheimer's Disease : JAD·Carlijn M MaasakkersJurgen A H R Claassen
Jul 16, 2020·The Journal of Clinical Hypertension·Per WändellKristina Sundquist
Sep 28, 2017·Clinical and Experimental Hypertension : CHE·Jiadela TeliewubaiYi Zhang
Sep 13, 2015·Current Cardiology Reports·Beje Thomas, Matthew R Weir
Mar 21, 2017·Journal of Hypertension·Giovanni CorraoGiuseppe Mancia
Oct 26, 2018·Hypertension·Federico ReaGiuseppe Mancia
Jan 20, 2017·The New England Journal of Medicine·David C Goff, William C Cushman
Aug 31, 2018·European Heart Journal·Bryan WilliamsUNKNOWN ESC Scientific Document Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.